BiotechTube

leflunomide + procarbazine hydrochloride

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Brain and Central Nervous System Tumors

Conditions

Brain and Central Nervous System Tumors

Trial Timeline

Feb 1, 1998 → May 1, 2001

NCT ID
NCT00003293

About leflunomide + procarbazine hydrochloride

leflunomide + procarbazine hydrochloride is a phase 3 stage product being developed by Pfizer for Brain and Central Nervous System Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT00003293. Target conditions include Brain and Central Nervous System Tumors.

What happened to similar drugs?

5 of 17 similar drugs in Brain and Central Nervous System Tumors were approved

Approved (5) Terminated (2) Active (12)
✅ExenatideAstraZenecaApproved
✅RivastigmineNovartisApproved
✅Genotropin (PN-180,307) SomatropinPfizerApproved
✅Genotropin + PlaceboPfizerApproved
✅Dotarem® + Gadovist®/Gadavist®GuerbetApproved
🔄Nivolumab + TemozolomideOno PharmaceuticalPhase 3
🔄Nivolumab + TemozolomideOno PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00003293Phase 3Completed

Competing Products

20 competing products in Brain and Central Nervous System Tumors

See all competitors
ProductCompanyStageHype Score
Abemaciclib + Endocrine therapyEli LillyPhase 1/2
39
Duloxetine + Sugar pillEli LillyPhase 2
27
Neurosteroid enantiomerOragenicsPhase 2
32
Patritumab deruxtecanDaiichi SankyoPhase 2
27
filgrastim + exatecan mesylateDaiichi SankyoPhase 1
29
Eribulin MesylateEisaiPhase 1
29
Pembrolizumab + LenvatinibEisaiPhase 2
42
Palonosetron (Aloxi) and DexamethasoneEisaiPhase 2
27
GLIADELEisaiPhase 2
35
Nivolumab + TemozolomideOno PharmaceuticalPhase 3
40
Nivolumab + TemozolomideOno PharmaceuticalPhase 3
40
Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastimEli LillyPhase 1
29
abemaciclib + abemaciclibEli LillyPhase 2
39
JNJ-17299425Johnson & JohnsonPhase 2
27
ABT-888AbbViePhase 1
29
Veliparib + PlaceboAbbViePhase 2
35
Iressa (Gefitinib)AstraZenecaPhase 2
27
Trastuzumab deruxtecanAstraZenecaPhase 2
42
ExenatideAstraZenecaApproved
43
AZD5213AstraZenecaPhase 1
29